Cargando…

Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis

SIMPLE SUMMARY: Lung cancer remains the leading cause of cancer-related mortality worldwide. Although early-stage non-small cell lung cancer (NSCLC) is likely to be controlled with stereotactic body radiation therapy (SBRT), approximately 18% of patients lead to recurrence. The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawayanagi, Subaru, Yamashita, Hideomi, Nozawa, Yuki, Takenaka, Ryosuke, Miki, Yosuke, Morishima, Kosuke, Ueno, Hiroyuki, Ohta, Takeshi, Katano, Atsuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405862/
https://www.ncbi.nlm.nih.gov/pubmed/36010853
http://dx.doi.org/10.3390/cancers14163859
_version_ 1784773981566402560
author Sawayanagi, Subaru
Yamashita, Hideomi
Nozawa, Yuki
Takenaka, Ryosuke
Miki, Yosuke
Morishima, Kosuke
Ueno, Hiroyuki
Ohta, Takeshi
Katano, Atsuto
author_facet Sawayanagi, Subaru
Yamashita, Hideomi
Nozawa, Yuki
Takenaka, Ryosuke
Miki, Yosuke
Morishima, Kosuke
Ueno, Hiroyuki
Ohta, Takeshi
Katano, Atsuto
author_sort Sawayanagi, Subaru
collection PubMed
description SIMPLE SUMMARY: Lung cancer remains the leading cause of cancer-related mortality worldwide. Although early-stage non-small cell lung cancer (NSCLC) is likely to be controlled with stereotactic body radiation therapy (SBRT), approximately 18% of patients lead to recurrence. The aim of this study was to identify prognostic factors and establish a predictive model for survival outcomes of patients with non-metastatic NSCLC treated with SBRT. Several radiomic features were selected as predictive factors and two prediction models were established from the pre-treatment computed tomography images of 250 patients in the training cohort. One radiomic factor remained a significant prognostic factor of overall survival (OS) (p = 0.044), and one predicting model could estimate OS time (mean: 37.8 months) similar to the real OS time (33.7 months). In this study, we identified one radiomic factor and one prediction model that can be widely used. ABSTRACT: Stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) leads to recurrence in approximately 18% of patients. We aimed to extract the radiomic features, with which we predicted clinical outcomes and to establish predictive models. Patients with primary non-metastatic NSCLC who were treated with SBRT between 2002 and 2022 were retrospectively reviewed. The 358 primary tumors were randomly divided into a training cohort of 250 tumors and a validation cohort of 108 tumors. Clinical features and 744 radiomic features derived from primary tumor delineation on pre-treatment computed tomography were examined as prognostic factors of survival outcomes by univariate and multivariate analyses in the training cohort. Predictive models of survival outcomes were established from the results of the multivariate analysis in the training cohort. The selected radiomic features and prediction models were tested in a validation cohort. We found that one radiomic feature showed a significant difference in overall survival (OS) in the validation cohort (p = 0.044) and one predicting model could estimate OS time (mean: 37.8 months) similar to the real OS time (33.7 months). In this study, we identified one radiomic factor and one prediction model that can be widely used.
format Online
Article
Text
id pubmed-9405862
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94058622022-08-26 Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis Sawayanagi, Subaru Yamashita, Hideomi Nozawa, Yuki Takenaka, Ryosuke Miki, Yosuke Morishima, Kosuke Ueno, Hiroyuki Ohta, Takeshi Katano, Atsuto Cancers (Basel) Article SIMPLE SUMMARY: Lung cancer remains the leading cause of cancer-related mortality worldwide. Although early-stage non-small cell lung cancer (NSCLC) is likely to be controlled with stereotactic body radiation therapy (SBRT), approximately 18% of patients lead to recurrence. The aim of this study was to identify prognostic factors and establish a predictive model for survival outcomes of patients with non-metastatic NSCLC treated with SBRT. Several radiomic features were selected as predictive factors and two prediction models were established from the pre-treatment computed tomography images of 250 patients in the training cohort. One radiomic factor remained a significant prognostic factor of overall survival (OS) (p = 0.044), and one predicting model could estimate OS time (mean: 37.8 months) similar to the real OS time (33.7 months). In this study, we identified one radiomic factor and one prediction model that can be widely used. ABSTRACT: Stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) leads to recurrence in approximately 18% of patients. We aimed to extract the radiomic features, with which we predicted clinical outcomes and to establish predictive models. Patients with primary non-metastatic NSCLC who were treated with SBRT between 2002 and 2022 were retrospectively reviewed. The 358 primary tumors were randomly divided into a training cohort of 250 tumors and a validation cohort of 108 tumors. Clinical features and 744 radiomic features derived from primary tumor delineation on pre-treatment computed tomography were examined as prognostic factors of survival outcomes by univariate and multivariate analyses in the training cohort. Predictive models of survival outcomes were established from the results of the multivariate analysis in the training cohort. The selected radiomic features and prediction models were tested in a validation cohort. We found that one radiomic feature showed a significant difference in overall survival (OS) in the validation cohort (p = 0.044) and one predicting model could estimate OS time (mean: 37.8 months) similar to the real OS time (33.7 months). In this study, we identified one radiomic factor and one prediction model that can be widely used. MDPI 2022-08-10 /pmc/articles/PMC9405862/ /pubmed/36010853 http://dx.doi.org/10.3390/cancers14163859 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sawayanagi, Subaru
Yamashita, Hideomi
Nozawa, Yuki
Takenaka, Ryosuke
Miki, Yosuke
Morishima, Kosuke
Ueno, Hiroyuki
Ohta, Takeshi
Katano, Atsuto
Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis
title Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis
title_full Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis
title_fullStr Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis
title_full_unstemmed Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis
title_short Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis
title_sort establishment of a prediction model for overall survival after stereotactic body radiation therapy for primary non-small cell lung cancer using radiomics analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405862/
https://www.ncbi.nlm.nih.gov/pubmed/36010853
http://dx.doi.org/10.3390/cancers14163859
work_keys_str_mv AT sawayanagisubaru establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT yamashitahideomi establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT nozawayuki establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT takenakaryosuke establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT mikiyosuke establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT morishimakosuke establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT uenohiroyuki establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT ohtatakeshi establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis
AT katanoatsuto establishmentofapredictionmodelforoverallsurvivalafterstereotacticbodyradiationtherapyforprimarynonsmallcelllungcancerusingradiomicsanalysis